Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects, Volume 2
Editat de Douglas L. Mayers, Jack D. Sobel, Marc Ouellette, Keith S. Kaye, Dror Marchaimen Limba Engleză Paperback – 12 aug 2018
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (2) | 1935.19 lei 6-8 săpt. | |
Springer International Publishing – 12 aug 2018 | 1935.19 lei 6-8 săpt. | |
Springer International Publishing – 12 iun 2018 | 2422.80 lei 6-8 săpt. | |
Hardback (2) | 1979.73 lei 38-44 zile | |
Springer International Publishing – 7 iul 2017 | 1979.73 lei 38-44 zile | |
Springer International Publishing – 7 iul 2017 | 2265.22 lei 38-44 zile |
Preț: 1935.19 lei
Preț vechi: 2037.04 lei
-5% Nou
Puncte Express: 2903
Preț estimativ în valută:
370.39€ • 388.58$ • 307.26£
370.39€ • 388.58$ • 307.26£
Carte tipărită la comandă
Livrare economică 29 ianuarie-12 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319836959
ISBN-10: 3319836951
Ilustrații: XXI, 855 p. 61 illus., 32 illus. in color.
Dimensiuni: 210 x 279 mm
Greutate: 1.93 kg
Ediția:Softcover reprint of the original 2nd ed. 2017
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3319836951
Ilustrații: XXI, 855 p. 61 illus., 32 illus. in color.
Dimensiuni: 210 x 279 mm
Greutate: 1.93 kg
Ediția:Softcover reprint of the original 2nd ed. 2017
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
Cuprins
History of Drug-Resistant Microbes.- Evolutionary Biology of Drug Resistance.- Pharmacology of Drug Resistance.- Drug Development for Drug-Resistant Pathogens.- Genetic Mechanisms of Transfer of Drug Resistance.- Mutations as a Basis of Antimicrobial Resistance.- Altered Drug Targets.- Enzymatic Modification of Drugs.- Reduced Drug Penetration.- Active Efflux Mechanism.- Biofilms.- Beta-Lactamases.- Penicillin Binding Proteins.- Aminoglycosides.- Tetracyclines and ChloramphenicolQuinolones.- Plasmid Mediated Quinolone Resistance to Macrolides, Lincosamides, and Streptogramins.- Mechanisms of Resistance in Metronidazole.- Glycopeptide-resistance in eneterococci.- Daptomycin Resistance.- Oxazolidinones.- PolymyxinsSulfonamides and Trimethoprim.- Antimycobacterial Agents.- Amphotericin (Polyenes).- Azoles.- Flucytosine.- Echinocandins.- Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans.- Herpes Nucleoside Drugs.- Influenza Drugs.- HIV Nucleoside Drugs.- HIV Non-Nucleoside Drugs.- HIV Protease Inhibitors.- HIV Entry Inhibitors.- HIV Integrase Inhibitors.- Hepatitis B.- Hepatitis C.- Agents for anaerobic protozoa.- Antimalarial Agents.- Agents for Leishmania.- Agents for Trypanosomes.- Agents for Toxoplasma.- Agents for Cryptosporidium.- Agents against Nematodes.- Agents against Trematodes and Cestodes.- Agents against Ectoparasites.
Notă biografică
Douglas L. Mayers is an infectious diseases specialist and is currently Chief Medical Officer (CMO) at Cocrystal Pharma. Dr. Mayers received his M.D. from University of Pennsylvania and has over 20 years of medical and clinical development experience spanning all phases of global clinical research and development and commercialization. He has worked with the United States Army Medical Research Institute of Infectious Diseases to discover and develop drugs against the Ebola virus. He has also served as the Head of HIV Clinical Studies Program and Department of HIV Disease Prevention at the Walter Reed Army Institute of Research and Naval Medical Research Institute. Previously, he was the Chief Medical Officer and Executive Vice President at Idenix Pharmaceuticals, where he directed the Infectious Disease programs and led numerous regulatory filings globally, including successful advancement of several anti-HCV candidates to the clinical phase. Prior to Idenix, he was the International Head/Vice President of the Virology Therapeutic Area at Boehringer Ingelheim where he led Phase 1 through 4 clinical studies for HIV and hepatitis programs. In addition to his extensive expertise in the industry and in research, Dr. Mayers is well-known in the academic sphere and is the author of over 95 peer-reviewed publications and book chapters.
Caracteristici
New chapters and authors on recent developments in drug resistance Expertise from over 197 international professionals in the field Discusses drug resistance genes and the implementation of genomic data Additional three new topics regarding increasingly important public health issues Includes supplementary material: sn.pub/extras